Primary small cell oesophageal carcinoma: A retrospective study of different ‎treatment modalities

Table 2 Clinical and treatment details of the 15 patients who received palliative chemotherapy

Patient	Age	Sex	PS	Stage	Site	CT	Cycles (n)	Palliative RT	Response	Survival (mo)
1	80	M	1	ES	Low	PE	6	No	PR	16
2	58	M	1	ES	Low	PE	6	No	PR	12
3	67	F	2	ES	Mid	P	4	No	PR	9
4	80	M	3	ES	Mid	P	2	No	UK	1.5
5	59	M	1	ES	Mid	PE	2	Yes	UK	2
6	70	F	1	ES	Low	PE	4	Yes	PR	12
7	53	F	0	ES	Low	CE	6	No	PR	10
8	62	F	2	ES	Mid	P	4	No	PR	7
9	65	M	0	ES	Low	PE	4	No	PR	3.5
10	81	F	3	ES	Low	None	0	No	NA	1
11	84	F	2	ES	Low	None	0	Yes	NA	1
12	86	M	1	LS	Low	P	2	Yes	SD	14
13	75	M	1	LS	Low	PE	4	No	PR	3
14	72	M	0	LS	Low1	ECX/CE	3/3	No	SD	13
15	75	F	1	LS	Low	PE	2	No	PR	5.5

¹Mixed pathology of small cell oesophageal cancer and squamous cell carcinoma. CE: Cisplatin and etoposide; CT: Chemotherapy; ED: Extensive stage; ECX: Epirubicin, cisplatin and capecitabine; F: Female; LD: Limited disease; M: Male; Mid: Middle; NA: Not applicable; Low: Lower; PE: Carboplatin and etoposide; PS: Performance status; PR: Partial response; RT: Radiotherapy; SD: Stable disease; UK: Unknown.